MediWound (MediWound) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is MediWound Short-Term Debt?

MediWound's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

MediWound Short-Term Debt Historical Data

The historical data trend for MediWound's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediWound Short-Term Debt Chart

MediWound Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

MediWound Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

MediWound Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

MediWound Short-Term Debt Related Terms

Thank you for viewing the detailed overview of MediWound's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MediWound (MediWound) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediWound Ltd (NAS:MDWD) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

M8W:Germany

Address

42 Hayarkon Street, Yavne, ISR, 8122745

Website

https://www.mediwound.com

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.